Sterility testing market seen hitting $5.15 billion by 2035

Market Research Future projects the global sterility testing market will rise from $1.88 billion in 2026 to $5.15 billion by 2035, fueled by tighter EU GMP rules, faster cell and gene therapy approvals, and a shift toward rapid microbial detection. The forecast points to stronger demand across biopharma manufacturing, outsourced testing and rapid-release quality control worldwide.

Why it matters: - Sterility testing is moving from a back-end quality check to a core compliance requirement as biologic and advanced therapy manufacturing expands. - The market’s growth reflects rising regulatory pressure, higher batch-volume testing needs and demand for faster release decisions. - Faster testing can shorten quarantine time, reduce contamination risk and speed patient access to sterile drugs.

What happened: - Market Research Future projected the global sterility testing market will reach $5.15 billion by 2035, up from $1.88 billion in 2026. - The forecast implies an 11.85% compound annual growth rate from 2026 to 2035. - The market was estimated at $1.69 billion in 2025. - The report tied growth to EU GMP Annex 1 enforcement, cell and gene therapy expansion and adoption of rapid sterility platforms. - The report also included sample and customization request links: Request a free sample and Ask for customization.

The details: - Revised EU GMP Annex 1 became effective in August 2023, with a two-year transition for lyophilization. - The regulation requires sterile manufacturers to validate contamination control strategies at critical processing steps. - PIC/S-member authorities in Australia, Canada and Singapore are adopting harmonized expectations. - Global biopharmaceutical R&D spending surpassed $260 billion in 2024. - By mid-2025, more than 3,400 cell and gene therapy clinical trials were active worldwide, up from 1,800 in 2021. - The FDA’s CBER approved 12 gene therapies from 2023 through 2025. - Sartorius, bioMérieux and Charles River Laboratories have invested more than $450 million in rapid microbial platforms since 2021. - Rapid sterility methods such as ATP bioluminescence, CO2 headspace analysis and qPCR can cut results from 14 days to 24-72 hours. - The European Pharmacopoeia’s Chapter 2.6.27 provides a validation framework for alternative rapid procedures. - At least six FDA pre-approval inspections in 2024 accepted rapid sterility results as the main release criterion. - Fully enclosed robotic sterility test isolators reduce analyst intervention from hours to minutes per batch. - China’s revised Drug Administration Law and NMPA guidance have doubled the number of registered GMP testing laboratories since 2021. - India’s Serum Institute and Bharat Biotech operate the world’s largest vaccine production campuses by unit volume.

Between the lines: - The report suggests the market is being reshaped by regulation and manufacturing complexity, not by discretionary healthcare demand. - Consumables still dominate because every test uses membranes, media or cartridges, creating recurring revenue for suppliers. - Rapid testing is becoming the strategic growth lane because it aligns with real-time release, lower contamination risk and tighter manufacturing timelines. - Outsourced testing is gaining share as smaller drug makers reduce fixed QC costs and contract manufacturers build testing capacity into fill-finish sites. - The report points to a long-term shift toward closed-loop, data-driven contamination control that links environmental monitoring with batch results.

What's next: - The report expects rapid microbial detection to become more common in release testing through the rest of the decade. - By 2030, a majority of newly approved biologics may use rapid sterility testing as the principal release criterion, the report said. - The FDA’s 2024 guidance on Process Analytical Technology for sterile drug products encourages continuous monitoring that could eventually reduce or replace end-point sterility tests. - Raman spectroscopy, impedance-based microbial sensing and micro-calorimetry are being piloted for continuous fill-finish lines. - Volume growth in Asia-Pacific and South America is expected to offset pricing pressure on traditional compendial testing.

The bottom line: - Sterility testing is shifting toward faster, automated and more tightly regulated workflows, with rapid methods and outsourced testing set to take a larger share of the market.